Beam Therapeutics (BEAM) Preferred Dividend Payments (2019 - 2020)
Beam Therapeutics (BEAM) reported Preferred Dividend Payments of $1.3 million for Q1 2020, down 56.9% year-over-year from $3.0 million in Q2 2019, and down 60.86% on a QoQ basis from $3.3 million in Q4 2019.
Beam Therapeutics (BEAM) has 2 years of Preferred Dividend Payments data on file, last reported at $1.3 million in Q1 2020.
- Quarterly Preferred Dividend Payments fell 56.9% year-over-year to $1.3 million in Q1 2020, while the trailing twelve-month figure through Dec 2020 was $1.3 million (down 89.96% YoY) and the FY2020 annual result came in at $1.3 million, down 89.96% from the prior year.
- Preferred Dividend Payments fell to $1.3 million in Q1 2020 per BEAM's latest filing, from $3.3 million in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $3.3 million in Q4 2019 and bottomed at $1.3 million in Q1 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Beam Therapeutics | 3.40 Bn | 3.40 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 1.28 Mn |
| Dec 31, 2019 | 3.26 Mn |
| Sep 30, 2019 | 3.26 Mn |
| Jun 30, 2019 | 3.23 Mn |
| Mar 31, 2019 | 2.96 Mn |